Literature DB >> 18533269

Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections.

Julia C Dombrowski1, Lisa G Winston.   

Abstract

OBJECTIVES: Methicillin-resistant Staphylococcus aureus (MRSA) infections can be difficult to treat. We evaluated the rate of clinical failure in appropriately-treated patients and determined risk factors for failure.
METHODS: We retrospectively studied a cohort of patients with invasive MRSA infections who completed recommended therapy at one hospital over a 7 year period.
RESULTS: Two-hundred and fifteen cases were included. Vancomycin monotherapy was given in 73%. Failure rates by infection site were as follows: osteomyelitis 37/81 (46%), epidural abscess five/18 (28%), surgical wound four/15 (27%), pneumonia eight/45 (18%), endocarditis five/32 (16%), bloodstream five/42 (12%), joint one/23 (4%), and meningitis zero/one (0%). In multivariate analysis, only a diagnosis of osteomyelitis was independently associated with relapse (p<0.001).
CONCLUSIONS: We found a high rate of treatment failure in an urban population among patients who completed recommended therapy, largely with vancomycin alone. Failure in osteomyelitis was particularly common. High quality comparative studies of antibiotic regimens for MRSA infections, particularly osteomyelitis, are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18533269      PMCID: PMC2579945          DOI: 10.1016/j.jinf.2008.04.003

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  18 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis.

Authors:  Naval G Daver; Samuel A Shelburne; Robert L Atmar; Thomas P Giordano; Charles E Stager; Charles A Reitman; A Clinton White
Journal:  J Infect       Date:  2007-01-02       Impact factor: 6.072

3.  Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.

Authors:  Jose M Eguia; Catherine Liu; Matthew Moore; Elizabeth M Wrone; Joan Pont; Julie L Gerberding; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2005-04-19       Impact factor: 9.079

4.  Risk factors and treatment outcomes in osteomyelitis.

Authors:  Alan D Tice; Pamela A Hoaglund; David A Shoultz
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

5.  Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model.

Authors:  Li-Yan Yin; Luca Lazzarini; Fan Li; C Melinda Stevens; Jason H Calhoun
Journal:  J Antimicrob Chemother       Date:  2005-04-27       Impact factor: 5.790

6.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  High versus standard dose vancomycin for osteomyelitis.

Authors:  Emmanuelle Boffi El Amari; Albert Vuagnat; Richard Stern; Mathieu Assal; Philippe Denormandie; Pierre Hoffmeyer; Louis Bernard
Journal:  Scand J Infect Dis       Date:  2004

8.  Vancomycin therapy and the progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis.

Authors:  Michael S Gelfand; Kerry O Cleveland
Journal:  South Med J       Date:  2004-06       Impact factor: 0.954

9.  Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin.

Authors:  C W Norden; M Shaffer
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

10.  Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Authors:  Feng-Yee Chang; James E Peacock; Daniel M Musher; Patricia Triplett; Brent B MacDonald; Joseph M Mylotte; Alice O'Donnell; Marilyn M Wagener; Victor L Yu
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

View more
  25 in total

1.  Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  The Concern for Vancomycin Failure in the Treatment of Pediatric Staphylococcus aureus Disease.

Authors:  Isaac P Thomsen
Journal:  Clin Infect Dis       Date:  2019-01-18       Impact factor: 9.079

Review 3.  Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.

Authors:  Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler
Journal:  Nat Rev Microbiol       Date:  2019-04       Impact factor: 60.633

Review 4.  Community-associated meticillin-resistant Staphylococcus aureus.

Authors:  Frank R DeLeo; Michael Otto; Barry N Kreiswirth; Henry F Chambers
Journal:  Lancet       Date:  2010-03-05       Impact factor: 79.321

Review 5.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

6.  Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Hydrogen/deuterium exchange mass spectrometry and site-directed disulfide cross-linking suggest an important dynamic interface between the two lysostaphin domains.

Authors:  Hai-Rong Lu; Mei-Gang Gu; Qiang Huang; Jin-jiang Huang; Wan-Ying Lu; Hong Lu; Qing-Shan Huang
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  Six weeks antibiotic therapy for all bone infections: results of a cohort study.

Authors:  R Farhad; P-M Roger; C Albert; C Pélligri; C Touati; P Dellamonica; C Trojani; P Boileau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-10       Impact factor: 3.267

9.  Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus.

Authors:  R Banerjee; M G Fernandez; N Enthaler; C Graml; K E Greenwood-Quaintance; R Patel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-23       Impact factor: 3.267

10.  Peripatetic health-care workers as potential superspreaders.

Authors:  Laura Temime; Lulla Opatowski; Yohan Pannet; Christian Brun-Buisson; Pierre Yves Boëlle; Didier Guillemot
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.